Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects With Resected Esophageal, or Gastroesophageal Junction Cancer

Next Previous
Trial Profile

A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects With Resected Esophageal, or Gastroesophageal Junction Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Adenocarcinoma; Carcinoma; Gastric cancer; Oesophageal cancer; Squamous cell cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms CheckMate 577
  • Sponsors Bristol-Myers Squibb

    • Most Recent Events

    • 09 Nov 2022 Results of cost effective analysis of adjuvant nivolumab versus current clinical practice (surveillance) in patients with EC/GEJC who have residual disease after neoadjuvant chemoradiotherapy followed by complete resection presented at the 25th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
    • 18 Mar 2022 Results of exposure response analyses of nivolumab as adjuvant treatment in patients with esophageal cancer or gastroesophageal junction cancer presented at the 123rd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 18 Mar 2022 Population-pharmacokinetics analysis was conducted to evaluate the clinical pharmacology profiling of nivolumab as adjuvant treatment in patients with esophageal cancer (EC) or gastroesophageal junction cancer from this trial, presented at the 123rd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top